201. Discovery of novel polysubstituted N -alkyl acridone analogues as histone deacetylase isoform-selective inhibitors for cancer therapy.
- Author
-
Wang Z, Zhao L, Zhang B, Feng J, Wang Y, Zhang B, Jin H, Ding L, Wang N, and He S
- Subjects
- Humans, Histone Deacetylase Inhibitors pharmacology, Histone Deacetylase Inhibitors chemistry, Molecular Structure, Structure-Activity Relationship, Cell Line, Tumor, Molecular Docking Simulation, Histone Deacetylases metabolism, Protein Isoforms metabolism, Cell Proliferation, Histone Deacetylase 1 metabolism, Histone Deacetylase 1 pharmacology, Repressor Proteins metabolism, Repressor Proteins pharmacology, Antineoplastic Agents pharmacology, Antineoplastic Agents chemistry, Neoplasms
- Abstract
Pan-histone deacetylase (HDAC) inhibitors often have some toxic side effects. In this study, three series of novel polysubstituted N -alkyl acridone analogous were designed and synthesised as HDAC isoform-selective inhibitors. Among them, 11b and 11c exhibited selective inhibition of HDAC1, HDAC3, and HDAC10, with IC
50 values ranging from 87 nM to 418 nM. However, these compounds showed no inhibitory effect against HDAC6 and HDAC8. Moreover, 11b and 11c displayed potent antiproliferative activity against leukaemia HL-60 cells and colon cancer HCT-116 cells, with IC50 values ranging from 0.56 μM to 4.21 μM. Molecular docking and energy scoring functions further analysed the differences in the binding modes of 11c with HDAC1/6. In vitro anticancer studies revealed that the hit compounds 11b and 11c effectively induced histone H3 acetylation, S-phase cell cycle arrest, and apoptosis in HL-60 cells in a concentration-dependent manner.- Published
- 2023
- Full Text
- View/download PDF